ClinicalTrials.gg
Enrolling by invitationNCT07590518Updated Nov 19, 2026

VR Therapies for IBD

An interventional study of Distraction VR and VR/AI CBT in Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn Disease (CD), sponsored by Brennan Spiegel. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Brennan Spiegel · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now Enrolling by invitationStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Planned enrollment
129th of 327
76 · median 50
Started
2026
with 23 others
No phase
131 of 463
35 open now
Primary completion
2027-06
later than 51 of 121 live
Registered
452nd of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 129th largest by planned enrollment of the 327 interventional ones that give a count, is one of 24 that started in 2026, is one of 131 with no phase, reaches primary completion later than 51 of the 121 other live ones, and was the 452nd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

Through a pilot randomized controlled trial (RCT), the aim is to test the clinical impact and feasibility of a AI-enhanced Virtual Reality (VR) Cognitive Behavioral therapy (CBT) program versus distraction VR among patients with inflammatory bowel disease (IBD) and anxiety. It is hypothesized that using VR/AI CBT may reduce anxiety and IBD symptoms, leading to improved overall physical, psychological, and social functioning when compared to distraction VR.

Read the detailed description

In this pilot randomized controlled trial (RCT), the investigators aim to test the feasibility and preliminary clinical impact of a novel virtual reality (VR) cognitive behavioral therapy (CBT) program supported by artificial intelligence (AI) vs. distraction VR control among patients with IBD and anxiety.

The investigators will conduct this pilot RCT with 76 participants with with IBD and anxiety to achieve the following aims: Aim 1-Establish the feasibility of using an 8-week VR/AI CBT program among patients with IBD and anxiety; Aim 2-Acquire preliminary data assessing the clinical impact of an 8-week VR/AI CBT program vs. distraction VR control among patients with IBD with anxiety.; Aim 3-Acquire exploratory data assessing the biomarker impact of an 8-week VR/AI CBT program vs. distraction VR control among IBD patients with anxiety.

Participants will be randomized 1:1 to each study arm via the REDCap randomization module with allocation tables created by PASS. Block randomization will be used with random permuted block sizes of 6, 8, or 10, accounting for 20% additional subjects from the original sample size to allow for dropouts. The investigators will stratify randomization by sex to ensure balance in each arm. The investigators will also stratify randomization by current use of psychotropic or mental health medications/ prior psychotherapy to maintain balance.

Assessments will be performed at baseline and bi-weekly during the 8-week study period; this is a common treatment length for VR trials. While IBD is a chronic disease, the investigators must first assess the potential efficacy of the 8-week intervention in this pilot trial before evaluating durability in a definitive efficacy RCT.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis (UC)
  • Crohn Disease (CD)
  • Anxiety

Keywords

  • Virtual Reality
  • Cognitive Behavioral Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stated willingness to comply with all study procedures, VR therapy regimen, and availability for the duration of the study
  • Age of 18 years or older
  • Confirmed diagnosis of IBD with concurrent anxiety, defined as a GAD-7 score of ≥10
  • Ability to read and write in English (VR/AI CBT program is currently only available in English)
  • Access to an internet-enabled device (android or iOS smartphone, or personal laptop or desktop computer) to complete surveys and has access to internet and email complete baseline and assessment surveys.

Exclusion criteria

Exclusion Criteria:

  • Have a condition that interferes with the safe use of VR usage, such as history of seizures, facial injuries precluding headset placement, significant visual or hearing impairment that impacts ability to see the VR images or follow audio instructions
  • Have cognitive impairments that would affect protocol participation.
  • Currently engaged in psychotherapy (Patients who are taking medications for anxiety or have previously engaged in psychotherapy but are not currently in therapy will remain eligible).
  • Have had an IBD related surgery (including perianal surgery) within the past 6 months or anticipated in the next 6 months
  • Anticipated to change their IBD inflammatory treatment during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    VR/AI CBT

    The VR/AI CBT program will be delivered through the Meta Quest 2 device and is self-administered and includes a network of environments arranged in a virtual clinic that participants experience at home though a protocolized, 8-week program. Depending on the module, experiences within the program last between 10-20 minutes. Participants will be prompted to regularly use the headset each week over the 8-week study period. The VR modules are reinforced with regularly scheduled messages and CBT exercises delivered by a webapp that is available on any smartphone or computer. The program progressively builds new skills and culminates in transitioning from using VR to applying the skills learned in VR to everyday life.

    Device: VR/AI CBT

  • Sham comparator
    Distraction VR

    Participants in the distraction VR group will receive the same Meta Quest 2 device but will only have access to a distraction-based VR therapy program that includes 2D nature videos (e.g., relaxing on a beach, swimming with dolphins). Similar to the VR/AI CBT arm, people in the distraction VR group will be prompted to regularly use the headset each week for the 8-week treatment period.

    Device: Distraction VR

Interventions

  • DeviceDistraction VR

    Distraction-based VR program with 2D nature videos to be used for 8-weeks for 10-20 minutes per week.

  • DeviceVR/AI CBT

    8-week protocolized VR/AI CBT program

06

What researchers measure

Primary outcomes

  1. Generalized Anxiety Disorder-7 (GAD-7)

    The GAD-7 is a 7-item scale for screening and assessing the severity of generalized anxiety disorder. It has a 2-week recall period and is scored on a 0-21 scale-0-4: minimal anxiety; 5-9: mild; 10-14: moderate; 15-21 severe. It has high reliability and criterion validity across many clinical contexts. The minimal clinically important difference (MCID) is 4 points.

    Time frame: Bi-weekly; Baseline through Week 8

  2. System Usability Scale (SUS)

    The SUS is a validated, widely-used ten-item Likert scale giving a global view of assessments of usability, with each item rated on a scale of 0 to 5. Higher scores indicate greater usability.

    Time frame: Week 8

Secondary outcomes

  1. Short Inflammatory Bowel Disease Questionnaire (SIBD-Q)

    The SIBDQ is a 10-item, disease-targeted Health-Related Quality of Life (HRQoL) measure that evaluates 4 domains: bowel symptoms, systemic symptoms, emotional function, and social function. Each item is rated on a 7-point Likert scale, with total scores ranging from 10 to 70, higher scores indicate a better HRQoL and fewer IBD symptoms. The SIBDQ has been validated to detect meaningful changes in HRQoL in an outpatient setting. The full version IBDQ, has been validated for its excellent internal consistency, test-retest reliability, and construct validity, distinguishing between active disease and remission, as well as convergent and divergent validity. The IBDQ is widely validated in clinical trials and real-world settings, making it a robust tool for assessing changes in HRQoL.

    Time frame: Baseline, Week 4, and Week 8

  2. Patient Reported Outcome 2 (PRO2 for Ulcerative Colitis)

    The PRO-2 is a simplified PRO measure used to assess Ulcerative Colitis (UC) activity. The PRO-2 focuses on rectal bleeding (ranging from 0-3; higher score indicates worse severity of bleeding) and average daily stool frequency. This tool provides a quick and reliable assessment of patient-reported disease activity. The PRO-2 has been validated against clinical markers of disease activity, such as endoscopic findings and biomarkers, and is sensitive to detecting changes in UC symptoms.Total PRO-2 scores range from 0 to 6, with higher scores indicating worse ulcerative colitis symptom severity.

    Time frame: Baseline, Week 4, and Week 8

  3. Patient Reported Outcome 3 (PRO3 for Crohn's Disease)

    The PRO-3 is a simplified PRO measures used to assess Crohn's Disease activity. The PRO-3 evaluates: abdominal pain (ranging from 0-3 with higher scores indicating worse abdominal pain), stool frequency (number of liquid or soft stools per day), and general well-being (5-point scale ranging from 0-4, higher score indicates worse general well-being). The PRO-3 has been validated against clinical markers of disease activity, such as endoscopic findings and biomarkers, and is sensitive to detecting changes in Crohn's Disease symptoms. Higher overall PRO-3 scores indicate worse Crohn's disease symptom severity.

    Time frame: Baseline, Week 4, and Week 8

  4. 29-item Patient Reported Outcomes Measurement System v2.1(PROMIS-29)

    The PROMIS-29 is a validated 29-item questionnaire to assess general Health-Related Quality of Life (HRQoL) and treatment response in individuals with IBD. The assessment includes questions in each of the following domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, and pain intensity. 28 of the items use a 5-point Likert response scale that is T-scored, 1-5 with higher T-scores representing more of the domain measured (higher physical function/ability to participate in social roles and activities= better; higher anxiety/depression/fatigue/sleep disturbance/ pain interference=worse). Pain intensity uses a numeric rating scale, 0 to 10 with higher scores indicating greater pain intensity.

    Time frame: Baseline, Week 4, and Week 8

  5. Visceral Sensitivity Index (VSI)

    GI symptom-specific anxiety as measured by the VSI. The VSI is 15 items, rated on 6-point Likert scale ranging from 1 (strongly agree) to 6 (strongly disagree).

    Time frame: Baseline, Week 4, and Week 8

Other outcomes

  1. Serum C-Reactive Protein (CRP)

    A blood test that measures for systemic inflammation. CRP is a protein made by the liver, and increases when there is inflammation in the body. This biomarker is routinely used in clinical settings to monitor IBD activity and predict relapses.

    Time frame: Baseline and Week 8

  2. Fecal Calprotectin (fCal)

    A stool sample that measures for gastrointestinal inflammation. fCal is released by neutrophils in the intestine during inflammation. This biomarker is routinely used in clinical settings to monitor IBD activity and predict relapses.

    Time frame: Baseline and Week 8

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 9 months is below that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 15, 2026
StartActual
Sep 29, 2026was Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 19, 2026
Start date
Jun 2026→Sep 29, 2026 (actual)
Nov 19, 2026
Contact
No study contact listed any more: removed k•••@cshs.org · •••0714; removed s•••@cshs.org · •••6721
Nov 19, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact removed k•••@cshs.org · •••0714Contact removed s•••@cshs.org · •••6721Contact removed (no phone or email listed)
  • University of Chicago · Chicago, United StatesContact removed A•••@bsd.uchicago.edu · •••0284Contact removed (no phone or email listed)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Jun 2026→Sep 29, 2026 (now actual)
    Contact No study contact listed any more: removed k•••@cshs.org · •••0714; removed s•••@cshs.org · •••6721
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact removed k•••@cshs.org · •••0714Contact removed s•••@cshs.org · •••6721Contact removed (no phone or email listed)
    • University of Chicago · Chicago, United StatesContact removed A•••@bsd.uchicago.edu · •••0284Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07590518
Lead sponsor
Brennan Spiegel
Responsible party
Brennan Spiegel (Director of Health Services Research; Professor of Medicine, Cedars-Sinai Medical Center) — Sponsor-investigator
First posted
May 15, 2026
Start date
Sep 29, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Brennan Spiegel, MD, MSHS
principal investigator · Cedars-Sinai Medical Center
David Rubin, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion